title: Efficacy and safety of intranasal buserelin acetate in the treatment of endometriosis: a review of six clinical trials and comparison with danazol.
abstract: The efficacy and safety of buserelin acetate in the treatment of endometriosis was studied in 4 open non-comparative trials and 2 open randomized comparative trials with danazol. 444 women were enrolled in the buserelin group and 89 in the danazol group. Treatment was for 6-10 months using 900-1200/micrograms intranasal buserelin/day and 400-800/micrograms oral danazol/day; patients were followed up for 6-8 months. Endometriotic lesions improved or disappeared in most women; pain (dysmenorrhoea, dyspareunia and pelvic pain) subsided rapidly. Most women had no, or alleviated, symptoms throughout follow-up, although ovarian function resumed promptly. Nearly a quarter of infertile women with a desire for children became pregnant. No significant differences between treatments emerged. Buserelin treatment was characterized by menopausal-like symptoms in most women, as well as by headache and nausea. Danazol treatment, which also gave rise to these effects, was accompanied by weight gain, myalgia and acne in a considerable proportion of women, as well as other anabolic and androgenic side effects. Buserelin would thus appear to be a safe and effective alternative to the standard therapy, danazol, in the treatment of endometriosis.
authors.affiliation: Clinical Research Department, Hoechst AG, Frankfurt am Main, West Germany.
authors.forename: H
authors.initials: H
authors.lastname: Trabant
authors.forename: W
authors.initials: W
authors.lastname: Widdra
authors.forename: S
authors.initials: S
authors.lastname: de Looze
mesh_terms: D000281:Administration, Intranasal; D002064:Buserelin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002979:Climacteric / Q000187:drug effects; D002986:Clinical Trials as Topic; D003613:Danazol / Q000627:therapeutic use*; D004715:Endometriosis / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D004958:Estradiol / Q000097:blood; D005260:Female; D006801:Humans; D007247:Infertility, Female / Q000188:drug therapy / Q000209:etiology; D010060:Ovulation / Q000187:drug effects; D011245:Pregnadienes / Q000627:therapeutic use*; D011247:Pregnancy; D016032:Randomized Controlled Trials as Topic; D012449:Safety
chemical_list: D011245:Pregnadienes; D004958:Estradiol; D003613:Danazol; D002064:Buserelin